EUVIMEDEUVIMED entdecken
Crossref

Effects on cerebral blood flow after single doses of the β 2 agonist, clenbuterol, in healthy volunteers and patients with mild cognitive impairment or Parkinson's disease

Thomas Lodeweyckx iD, Jan de Hoon, Koen Van Laere, Edgar Bautista, Gaia Rizzo, Courtney Bishop, Eugenii Rabiner, Renee S Martin, Anthony Ford, Gabriel Vargas

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.16160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Thomas Lodeweyckx und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Pharmacology, Department of Pharmaceutical and Pharmacological Sciences, Catholic University Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Clenbuterol, Cerebrovascular Circulation, Cognitive Dysfunction, Adrenergic beta-2 Receptor Agonists. Die Arbeit nennt 54 Literaturangaben. Gefördert von: Curasen Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Cerebral hypometabolism occurs years prior to a diagnosis of neurodegenerative diseases and coincides with reduced cerebral perfusion and declining noradrenergic transmission from the locus coeruleus. In pre‐clinical models, β‐adrenoceptor (β‐AR) agonists increase cerebrocortical glucose metabolism, and may have therapeutic potential for neurodegenerative diseases. This study investigated the safety and effects on regional cerebral blood flow (rCBF) of the oral, brain‐penetrant β 2 ‐AR agonist, clenbuterol, in healthy volunteers (HV) and patients with mild cognitive impairment (MCI) or Parkinson's disease (PD).

Methods

This study evaluated the safety and effects on cerebral activity of the oral, brain‐penetrant, β 2 ‐AR agonist clenbuterol (20–160 μg) in healthy volunteers and patients with MCI or PD. Regional CBF, which is tightly coupled to glucose metabolism, was measured by arterial spin labelling MRI in 32 subjects (25 HV and 8 MCI or PD) across five cohorts. In some cohorts, low doses of nadolol (1–5 mg), a β‐AR antagonist with minimal brain penetration, were administered with clenbuterol to control peripheral β 2 ‐AR responses.

Results

Significant, dose‐dependent increases in rCBF were seen in multiple brain regions, including hippocampus, amygdala and thalamus, following the administration of clenbuterol to HVs (mean changes from baseline in hippocampal rCBF of −1.7%, 7.3%, 22.9%, 28.4% 3 h after 20, 40, 80 and 160 μg clenbuterol, respectively). In patients with MCI or PD, increases in rCBF following 80 μg clenbuterol were observed both without and with 5 mg nadolol (in hippocampus, 18.6%/13.7% without/with nadolol). Clenbuterol was safe and well‐tolerated in all subjects; known side effects of β 2 ‐agonists, including increased heart rate and tremor, were mild in intensity and were blocked by low‐dose nadolol.

Conclusions

The effects of clenbuterol on rCBF were evident both in the absence and presence of low‐dose nadolol, suggesting central nervous system (CNS) involvement. Concomitant inhibition of the peripheral effects of clenbuterol by nadolol confirms that meaningful β 2 ‐AR antagonism in the periphery was achieved without interrupting the central effects of clenbuterol on rCBF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClenbuterolCerebrovascular CirculationCognitive DysfunctionAdrenergic beta-2 Receptor AgonistsParkinson DiseaseHumansMaleFemaleAgedMiddle AgedAdultMagnetic Resonance ImagingDose-Response Relationship, DrugNadololHealthy VolunteersBrainYoung Adult

Stichwörter der Autor:innen

arterial spin labelling MRIclenbuterolnadololneurodegenerationnoradrenergic transmissionregional cerebral blood flowβ‐Adrenoceptor

Substanzen

ClenbuterolAdrenergic beta-2 Receptor AgonistsNadolol

Autor:innen und Institutionen

  • Center for Clinical Pharmacology, Department of Pharmaceutical and Pharmacological Sciences, Catholic University Leuven, Leuven, Belgium.
  • Division of Nuclear Medicine, University Hospital Leuven and Nuclear Medicine and Molecular Imaging, KU Leuven, Leuven, Belgium.
  • CuraSen Therapeutics, San Carlos, California, USA.
  • Invicro, London, UK.
  • Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

ORCID-Profile: Thomas Lodeweyckx

Förderung

  • Curasen Therapeutics

Zitieren

APA

Lodeweyckx, T., de Hoon, J., Van Laere, K., Bautista, E., Rizzo, G., Bishop, C., Rabiner, E., Martin, R. S., Ford, A., & Vargas, G. (2024). Effects on cerebral blood flow after single doses of the β 2 agonist, clenbuterol, in healthy volunteers and patients with mild cognitive impairment or Parkinson's disease. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16160

Vancouver

Lodeweyckx T, de Hoon J, Van Laere K, Bautista E, Rizzo G, Bishop C, et al. Effects on cerebral blood flow after single doses of the β 2 agonist, clenbuterol, in healthy volunteers and patients with mild cognitive impairment or Parkinson's disease. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16160

BibTeX
@article{Lodeweyckx2024,
  author = {Lodeweyckx, Thomas and de Hoon, Jan and Van Laere, Koen and Bautista, Edgar and Rizzo, Gaia and Bishop, Courtney and Rabiner, Eugenii and Martin, Renee S and Ford, Anthony and Vargas, Gabriel},
  title = {Effects on cerebral blood flow after single doses of the β 2 agonist, clenbuterol, in healthy volunteers and patients with mild cognitive impairment or Parkinson's disease},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.16160}
}
Kostenlos starten →